Xeris Pharmaceuticals: Q3 Earnings Insights

Shares of Xeris Pharmaceuticals XERS moved higher by 4.6% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share increased 71.31% over the past year to ($0.35), which beat the estimate of ($0.52).

Revenue of $9,448,000 higher by 2908.92% year over year, which beat the estimate of $4,480,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Nov 09, 2020

Time: 08:30 AM

ET Webcast URL: https://www.directeventreg.com/der/toRegistration.action

Technicals

52-week high: $9.69

52-week low: $1.42

Price action over last quarter: Up 73.25%

Company Overview

Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. Its pipeline products are Diazepam, Pramlintide-Insulin, Self-Administered Glucagon, and others.